NRGXQ

 
Common Stock SEC Reporting - Delinquent
Pink No Information
Contact Info
  • One Bridge Plaza
  • Fort Lee, NJ 07024

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2011 10-Q
CIK 0000356591
Fiscal Year End 12/31
OTC Marketplace Pink No Information
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Adrian Adams CEO
Andrew Koven President, Chief Admin. Officer
Reginald A. Hardy Vice President
Company Directors
Adrian Adams Chairman
Reginald A. Hardy
Clark A. Johnson
Andrew Koven
Service Providers
Accounting/Auditing Firm

Not Available
Securities Counsel

Not Available
Investor Relations Firm

Not Available
Company History
  • Note=2-04 company is in the development stage, developing proprietary gene therapies for treating central nervous system disorders
  • Formerly=Change Technology Partners, Inc. until 2-04
  • Note=9-00 State of Incorporation New Mexico changed to Delaware concurrent with name change
  • Formerly=Arinco Computer Systems, Inc until 9-00
NRGXQ Security Details
Share Structure
Market Value1 $41,997 a/o Jun 23, 2017
Authorized Shares Not Available
Outstanding Shares 27,997,701 a/o May 01, 2011
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01
Shareholders
Shareholders of Record 268 a/o Mar 25, 2011
Short Selling Data
Short Interest 0 (-100%)
Nov 13, 2015
Significant Failures to Deliver No

1Market Value calculated only for respective security